Mode
Home
Conditions Medications Drug Pipeline Weekly Digests Questions
Text Size
Log in / Sign up
Home › Medications › thymosin α1

thymosin α1

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis of immunomodulatory therapies for sepsis mortality
Rheumatology Meta-analysis
Network meta-analysis of immunomodulatory therapies for sepsis mortality Ulinastatin and other immune drugs may lower death risk in sepsis
This systematic review and network meta-analysis of 76 RCTs in 22,194 patients with sepsis synthesized evidence on immunomodulatory therapie…
A large review of 76 trials found ulinastatin and other immune therapies can reduce death risk in sepsis patients.
Frontiers May 12, 2026
Thymosin alpha1 added to standard therapy improved 90-day transplant-free survival in 73 patients with HBV-related acute-on-chronic liver failure
Gastroenterology RCT
Thymosin alpha1 added to standard therapy improved 90-day transplant-free survival in 73 patients with HBV-related acute-on-chronic liver failure Thymosin alpha1 may improve survival in hepatitis B liver failure patients
This open-label randomized controlled trial enrolled 73 patients with hepatitis B virus-related acute-on-chronic liver failure.
Adding thymosin alpha1 to standard therapy helped hepatitis B liver failure patients survive longer without needing a transplant.
Apr 9, 2026